ClinicalTrials.gg
CompletedNCT03288051Updated May 15, 2019

Effects of Intraoperative, Goal-directed Crystalloid vs. Colloid Fluid Resuscitation on Free Flaps

An interventional study of Fluid management and Norepinephrine in Optimal Tissue Perfusion, sponsored by Szeged University. Completed at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-15.

Sponsored by Szeged University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Apr 2014, registered Aug 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Maintaining satisfactory tissue perfusion is an essential of success during reconstructive free flap surgery following malign oral cavity tumours. Intra- and postoperative goal-directed fluid therapy is an appropriate tool for that. Continuous cardiac output monitoring based fluid loading (complemented with vasopressor and/or inotropes if necessary) might be superior to conventional, central venous and arterial pressure monitoring in terms of morbidity, complications, optimal fluid balance and days spent in hospital. However, there is no data describing the effects of goal-directed fluid therapy (crystalloid or colloid) on microcirculation of free flaps implanted in the oral cavity during the post-operative period. The aim of this study is to observe the effects of continuous macrohaemodynamic monitoring based, goal-directed fluid therapy on microcirculation of forearm flaps during the perioperative period.

02

Conditions studied

  • Optimal Tissue Perfusion
03

In context

Lead sponsor

Szeged University is the lead sponsor of 56 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18
  • Tumour location: intraoral
  • Free flap type: radial forearm
  • Signed informed concent form

Exclusion criteria

Exclusion Criteria:

  • Vulnerable subject as defined in International Standards Organization 14155:2011
  • End stage oral cancer
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Crystalloid group

    Other: Fluid management · Drug: Norepinephrine · Drug: Dobutamine

  • Active comparator
    Colloid group

    Other: Fluid management · Drug: Norepinephrine · Drug: Dobutamine

Interventions

  • OtherFluid management

    Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.

  • Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.

  • Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.

06

What researchers measure

Primary outcomes

  1. Changes of Pulse pressure variation during the operation and the post-operative 24 hours

    Time frame: 24 hours

  2. Assesment of free falp microcirculation by laser dopler flowmetry method.

    Time frame: 24 hours

  3. Total need of Norepinephrine and Dobutamine during surgery and the post-operative 24 hours.

    Time frame: 24 hours

  4. Changes of Cardiac Index during the operation and the post-operative 24 hours.

    Time frame: 24 hours

  5. Mean arterial pressure during the operation and the post-operative 24 hours.

    Time frame: 24 hours

Secondary outcomes

  1. Length of Intensive Care Unit stay

    Time frame: 24 hours

  2. Number of surgical or non-surgical complications.

    Time frame: 24 hours

  3. Length of Hospital stay

    Time frame: 10 days

07

Study locations

1 site
  • Department of Anaesthesiology and Intensive Therapy
    Szeged, Csongrád 6725, Hungary
08

References and documents

Publications

  • Salzwedel C, Puig J, Carstens A, Bein B, Molnar Z, Kiss K, Hussain A, Belda J, Kirov MY, Sakka SG, Reuter DA. Perioperative goal-directed hemodynamic therapy based on radial arterial pulse pressure variation and continuous cardiac index trending reduces postoperative complications after major abdominal surgery: a multi-center, prospective, randomized study. Crit Care. 2013 Sep 8;17(5):R191. doi: 10.1186/cc12885. PubMed 24010849 ↗
  • Holzle F, Rau A, Loeffelbein DJ, Mucke T, Kesting MR, Wolff KD. Results of monitoring fasciocutaneous, myocutaneous, osteocutaneous and perforator flaps: 4-year experience with 166 cases. Int J Oral Maxillofac Surg. 2010 Jan;39(1):21-8. doi: 10.1016/j.ijom.2009.10.012. Epub 2009 Nov 26. PubMed 19944567 ↗
  • Cecconi M, Hofer C, Teboul JL, Pettila V, Wilkman E, Molnar Z, Della Rocca G, Aldecoa C, Artigas A, Jog S, Sander M, Spies C, Lefrant JY, De Backer D; FENICE Investigators; ESICM Trial Group. Fluid challenges in intensive care: the FENICE study: A global inception cohort study. Intensive Care Med. 2015 Sep;41(9):1529-37. doi: 10.1007/s00134-015-3850-x. Epub 2015 Jul 11. Erratum In: Intensive Care Med. 2015 Sep;41(9):1737-8. doi: 10.1007/s00134-015-4003-y.. multiple investigator names added. PubMed 26162676 ↗
  • Laszlo I, Janovszky A, Lovas A, Vargan V, Oveges N, Tanczos T, Mikor A, Trasy D, Loderer Z, Piffko J, Szabo A, Molnar Z. Effects of goal-directed crystalloid vs. colloid fluid therapy on microcirculation during free flap surgery: A randomised clinical trial. Eur J Anaesthesiol. 2019 Aug;36(8):592-604. doi: 10.1097/EJA.0000000000001024. PubMed 31157652 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Feb 2017, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2017
First posted
Sep 19, 2017
StartActual
Apr 28, 2014
Primary completionActual
Feb 28, 2017
CompletionActual
Sep 19, 2018
Last update
May 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03288051
Lead sponsor
Szeged University
Collaborators
Department of Oral and Maxillofacial Surgery, University of Szeged, Institute of Surgical Research, University of Szeged
Responsible party
Zsolt Molnár, MD, PhD, DEAA (head of department, Szeged University) — Principal investigator
First posted
Sep 19, 2017
Start date
Apr 28, 2014
Primary completion
Feb 28, 2017
Completion
Sep 19, 2018
Last update
May 15, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Norepinephrine · Dobutamine

Start the discussion